Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
31,523,534
-
Total 13F shares
-
1,361,542
-
Share change
-
+844,769
-
Total reported value
-
$13,365,000
-
Price per share
-
$9.82
-
Number of holders
-
17
-
Value change
-
+$7,995,959
-
Number of buys
-
15
-
Number of sells
-
4
Institutional Holders of ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) as of Q1 2021
As of 31 Mar 2021,
ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,361,542 shares.
The largest 10 holders included
INGALLS & SNYDER LLC, AWM Investment Company, Inc., Ikarian Capital, LLC, JPMORGAN CHASE & CO, CREDIT SUISSE AG/, MARSHALL WACE, LLP, Federation des caisses Desjardins du Quebec, MORGAN STANLEY, Gradient Capital Advisors, LLC, and SUSQUEHANNA INTERNATIONAL GROUP, LLP.
This page lists
18
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.